National Pharmaceutical Council – Trademark Portfolio

Entity Type: 03

National Pharmaceutical Council holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include GOING BELOW THE SURFACE and COMPARATIVE EFFECTIVENESS RESEARCH DAILY NEWSFEED. The owner is based in Washington, DC.

Suite 800

1717 Pennsylvania Ave. NW

Washington, DC 20006

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

National Pharmaceutical Council's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (2 filings)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does National Pharmaceutical Council have?

National Pharmaceutical Council has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does National Pharmaceutical Council file in?

National Pharmaceutical Council files trademarks across 1 Nice Classification class. The most active classes are Class 41 (Education & Entertainment). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are National Pharmaceutical Council's most well-known trademarks?

National Pharmaceutical Council's registered trademark portfolio includes well-known marks such as GOING BELOW THE SURFACE and COMPARATIVE EFFECTIVENESS RESEARCH DAILY NEWSFEED. These are among 2 currently registered trademarks in the portfolio.

What is National Pharmaceutical Council's trademark registration success rate?

National Pharmaceutical Council has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.